Press releases

Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announces today that revenue and EBITA for the full year 2019 were higher than previous estimates. Full-year revenue was approximately SEK 14,150 –14,250 M and EBITA approximately SEK 6,200 – 6,300 M, excluding...

01/16/2020 - 19:00
Regulatory

Dova Pharmaceuticals, Inc., a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™) has been granted Orphan Drug Designation[1] (ODD) by the US Food and Drug Administration (FDA) for avatrombopag for the potential treament of Chemotherapy-Induced...

12/21/2019 - 08:00

SobiTM and Sanofi today announced that the first patient has been dosed in the phase 3, open-label, interventional study of BIVV001 (rFVIIIFc-VWF-XTEN), in patients with severe haemophilia A (XTEND-1 study; NCT04161495). Sobi and Sanofi are development partners for...

12/11/2019 - 08:00

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented additional analyses from the phase 3 study – core and extension phase - with avatrombopag (AVA) for the treatment of immune thrombocytopenia (ITP), at the 61st...

12/09/2019 - 07:05

Dova Pharmaceuticals, a wholly owned subsidiary of Swedish Orphan Biovitrum AB (publ) (Sobi™), presented data on the cost effectiveness of Doptelet® (avatrombopag) for the treatment of thrombocytopenia in patients with chronic liver diseases (CLD) who are scheduled to...

12/09/2019 - 07:00

Press contacts

Subscribe to our press releases and financial reports